Literature DB >> 34051030

A Ten-year Surveillance of P. aeruginosa Bloodstream Infections in a Tertiary Care Hospital: Trends and Risk Factors for Mortality.

Mera A Ababneh1, Abeer M Rababa'h1, Basima A Almomani1, Abeer M Ayoub1, Sayer I Al-Azzam1.   

Abstract

BACKGROUND: Pseudomonas aeruginosa (P. aeruginosa) is a leading cause of nosocomial bloodstream infections worldwide. This study aimed to evaluate the incidence of P. aeruginosa bloodstream infections and to identify predictors of 30-day mortality.
METHODS: A retrospective study was conducted in an academic tertiary hospital in Jordan. The medical records of patients hospitalized over ten years (January 1, 2008- December 31, 2017) were reviewed to identify patients' positive blood culture of P. aeruginosa. Annual incidence, antimicrobial susceptibility patterns, and risk factors for 30-day mortality were analyzed.
RESULTS: A total of 169 cases of P. aeruginosa bloodstream infection were identified, with an overall incidence rate of 0.23 case/1000 admission. The overall crude 30-day mortality was 36.7%. Receipt of corticosteroids (OR =4.5; p= 0.0017), severe sepsis and septic shock (OR = 2.7; p = 0.0476), admission to intensive care unit (OR= 5.9; p= 0.0004), end-stage renal disease (OR=4.1; p=0.0123), inappropriate empirical therapy (OR=3.2; p=0.0143), and inappropriate definitive therapy (OR=2.9; p=0.0110) were identified as independent risk factors for mortality.
CONCLUSION: The annual incidence of P. aeruginosa BSIs was fluctuating over ten years period. Several predictors for 30-day mortality in patients with P. aeruginosa BSIs were identified, including inappropriate empirical and definitive therapy. This article is protected by copyright. All rights reserved.

Entities:  

Year:  2021        PMID: 34051030     DOI: 10.1111/ijcp.14409

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  1 in total

1.  A prediction and interpretation machine learning framework of mortality risk among severe infection patients with pseudomonas aeruginosa.

Authors:  Chen Cui; Fei Mu; Meng Tang; Rui Lin; Mingming Wang; Xian Zhao; Yue Guan; Jingwen Wang
Journal:  Front Med (Lausanne)       Date:  2022-07-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.